Adelene Q. Perkins

Infinity Pharmaceuticals

Adelene Perkins serves as Infinity’s chief executive officer and Infinity’s chair. Prior to being named CEO, she served as Infinity’s President. She joined Infinity in June 2002 as executive vice president and chief business officer. Prior to joining Infinity, she served as vice president of business and corporate development of TransForm Pharmaceuticals where she was also an early member of the management team that built the company prior to its acquisition by J&J. Earlier in her career, Adelene formed and served as chief executive officer of MetaMorphix, a joint venture between Genetics Institute and Johns Hopkins University. In addition to chairing the Infinity board, she is on the boards of Bruker Corporation, Massachusetts General Hospital, BIO (Biotechnology Industry Organization), the Massachusetts Biotechnology Council, and Project Hope… She received her M.B.A. from Harvard Business School and her B.S. in chemical engineering from Villanova University.

Year appointed: 2010